康哲药业(00867.HK)中期股东应占溢利增长22.2%至11.7亿元每股派0.1883元
格隆汇8月16日丨康哲药业(00867.HK)公告，截至2019年6月30日止6个月，公司营业额29.64亿元人民币，同比增长11.7%；公司拥有人应占溢利11.7亿元，同比增长22.2%；每股盈利0.4717元，宣派中期股息每股人民币0.1883元，较去年同期增长22.6%。
若将两票制收入还原则该集团报告期营业额为人民币3,401.5百万元，较去年同期的人民币2,974.3百万元增长14.4%，主要因为产品销售数量的增加。报告期内，该集团毛利率为74.8%，较去年同期的70.9%增加3.9个百分点，主要因为药品进口关税税率下降以及增值税税率下降。
2019年上半年，4+7带量采购政策落地实施、医保目录调整工作方案公布、医药行业会计信息检查工作开启、首批重点监控药品目录发布等，各项政策已全面进入实施与推进过程。面对医药行业的重塑期，该集团不忘初心，一方面以国际视野积极布局可给予中国患者全新治疗方案的创新产品，稳固和扩大本集团的产品优势与竞争力。另一方面，该集团深化全国学术网络以巩固现有产品的学术差异，进一步扩大产品学术影响力，使该集团于报告期内实现良好的业绩增长。
期间该集团主要通过投资海外研发公司股权或达成战略性合作，布局多个不同创新程度、不同发展阶段的创新产品，以保障该集团在短、中、长期都有创新产品陆续投入市场。于报告期内，该集团获得了四个拥有足够竞争优势、可满足中国市场尚未满足临床需求的创新产品，其中，两个已在美国、欧盟等区域上市，另外两个正处于临床研究阶段。截至2019年6月30日，该集团共拥有眼科、皮肤科、神经系统、抗肿瘤、免疫系统、消化系统、抗感染、内分泌系统领域的十三个创新产品。
公告显示，该集团心脑血管线主要产品包括新活素、波依定、黛力新。于报告期内，心脑血管线实现收入人民币1,341.1百万元，较去年同期增长3.7%。若将两票制收入还原，则心脑血管线实现收入人民币1,940.4百万元，较去年同期增长14.7%，占该集团还原两票制营业额的57.0%。
该集团眼科线主要产品为施图伦滴眼液，于报告期内，眼科线实现收入人民币115.2百万元，较去年同期增长9.5%；该集团其他销售与推广的产品实现收入人民币394.8百万元，较去年同期增长21.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
